Abzena, a contract development and manufacturing organization (CDMO) specializing in complex biologics and bioconjugates, has announced an expansion of its quality control (QC) testing capabilities with a new microbiology lab in San Diego. The new facility is dedicated to enhancing analytical services for antibodies through rapid microbiology release testing and improved scalability via advanced materials separation. This expansion aims to better align with industry standards and regulatory requirements, optimize production capacity, and minimize cross-contamination risks. Designed as a standalone space, the lab is intended to segregate different types of microbiological testing, thereby enhancing efficiency and ensuring high yields, reaching up to 99% for clinical materials. Sean O’Brien, SVP and San Diego Site Head, stated that the expanded lab will advance testing and report development, further contributing to medical progress and high-quality testing services. The lab’s increased size allows for additional equipment, including a biosafety cabinet (BSC) and two new incubators, ensuring the facility can scale to meet future demands. Overall, this expansion underscores Abzena’s commitment to providing state-of-the-art services and maintaining its leadership position in biologic manufacturing.
Enhancing Capabilities and Scaling for the Future
Abzena, a CDMO specializing in complex biologics and bioconjugates, has announced the expansion of its quality control testing capabilities with a new microbiology lab in San Diego. This facility is dedicated to enhancing analytical services for antibodies through rapid microbiology release testing and improved scalability via advanced materials separation. The expansion aims to better align with industry standards, optimize production capacity, and minimize cross-contamination risks. Designed as a standalone space, the lab will segregate different types of microbiological testing, enhancing efficiency and ensuring high yields, up to 99% for clinical materials. Sean O’Brien, SVP and San Diego Site Head, mentioned that the new lab will advance testing and report development, contributing to medical progress and providing high-quality testing services. Its increased size allows for additional equipment like a biosafety cabinet (BSC) and two new incubators, ensuring the facility can scale to meet future demands. Overall, this expansion underscores Abzena’s commitment to state-of-the-art services and maintaining its leadership in biologic manufacturing.
